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Abstract
Background
Depression is highly prevalent among patients newly starting antiretroviral treatment (ART)
in Malawi and many other countries. Untreated depression at ART initiation can disrupt the
HIV care continuum. Effective approaches for depression screening and treatment exist for
low-resource settings, but they are rarely applied. Identifying effective implementation strat-
egies are critical.
Methods
A pilot program integrated depression screening and treatment into routine HIV care using
existing staff at two public health clinics in Malawi in two phases; a screening-only “control”
phase and an active “intervention” phase. During the intervention phase, providers pre-
scribed antidepressants or referred patients for Friendship Bench problem-solving therapy.
We evaluated the program’s impact on retention in HIV care, viral suppression, and depres-
sion remission at 6 months using tabular comparisons and log-binomial models to estimate
adjusted risk ratios and mean differences among the intervention group relative to the con-
trol group.
Results
Nearly all consenting participants were screened for depression appropriately and 25% had
mild to severe depressive symptoms. During the intervention phase, 86% of participants
with mild depressive symptoms started Friendship Bench therapy and 96% of participants
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with moderate to severe depressive symptoms started antidepressants. Few participants in
the intervention group received consistent depression treatment over their first 6 months in
care. In the adjusted main analysis, program exposure did not demonstrably affect most
HIV or mental health outcomes, though the probability of currently being on ART at 6 months
was significantly lower among the intervention group than the control group [RR 0.6(95%CI:
0.4–0.9)].
Conclusions
While it is feasible to integrate depression screening and treatment initiation into ART initia-
tion, providing ongoing depression treatment over time is challenging. Similar implementa-
tion science studies focused on maintaining depression management will be increasingly
important as we strive to understand and test the best ways to implement evidence-based
depression treatment within HIV care.
Introduction
The burden of depression among people living with HIV in Malawi is high, ranging between
1–19% [1–4], as in other sub-Saharan African countries [5]. Depression is associated with
poor HIV care engagement and ultimately increased HIV-related mortality and morbidity [5–
10]. The mechanisms through which depression undermines HIV care engagement are not
fully clear. However, loss of interest, poor concentration, poor motivation, reduced self-effi-
cacy, fatigue, hopelessness, and suicidality–key characteristics of depression–are all factors
which can impair adherence and appointment attendance [8, 10, 11]. Fortunately, depression
treatment programs have been developed that have the potential to improve both HIV care
and mental health outcomes, with a small but growing number of interventions adapted for
low- and middle-income countries [12–17]. In places such as Malawi, where nearly 10% of the
adult population is living with HIV [18] and nearly a quarter of people living with HIV are lost
to care in the first year of treatment [19–21], incorporating depression screening and treat-
ment into HIV care may be key to improving engagement in care across the HIV care
continuum.
There are limited resources for mental health care in Malawi, and a dearth of mental health
infrastructure and specialists. Malawi treats mental healthcare as a specialized service, offered
only by specialists in tertiary settings. There are only three psychiatrists and three functioning
psychiatric hospitals in the country [22]. In such settings where it is unlikely that the number
of specialists and infrastructure could grow rapidly enough to meet the demands of the popu-
lation, task-shifting programs–models of care that shift specialized services to non-specialists
[23]–are a popular, and often cost effective strategy for providing mental health services [24–
26]. Of the few depression treatment interventions developed for the sub-Saharan region,
most employ a task-shifting model [16, 27–32].
Two notable task-shifting interventions include algorithm-based care for depression [31–
33] and the Friendship Bench behavioral activation and problem-solving therapy [29]. Algo-
rithm-based care is a resource-efficient, task-sharing model for prescribing antidepressant
management in non-psychiatric settings. This model of care has demonstrated safety, feasibil-
ity, and acceptability when adapted for HIV care and delivered by general practice medical
providers in Cameroon, Tanzania and Uganda [31–33]. Developed over many years of forma-
tive research in Zimbabwe, the Friendship Bench is patient-centered counseling that teaches
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patients how to identify triggers and effectively manage stressful life events by learning or reac-
tivating problem solving skills [29, 34]. These programs as well as others have proven efficacy
in improving depression outcomes, though evidence on improvements in HIV care outcomes
has been mixed [27, 31–33, 35–37]. Further investment in understanding the feasibility of
task-shifting program implementation and the effectiveness of these models of depression care
is needed to meet the mental health care needs of people living with HIV.
The Malawi Ministry of Health (MOH) has recognized the importance of addressing the
burden of depression among people living with HIV as a means of improving engagement in
HIV care. The MOH has also prioritized the integration of mental health services into other
general health services and the development of mental health capacity of general providers
[38–40]. Expanding the growing nidus of investment in mental health care programming and
capacity development, the MOH implemented a pilot program integrating depression man-
agement into HIV care at two public clinics in Lilongwe, Malawi, using both algorithm-guided
depression treatment and adapted Friendship Bench therapy [41]. Inspired by the key princi-
ples of implementation science, we use a multiple-baseline design to investigate the program’s
impact on HIV care and depression outcomes.
Methods
Objectives
The main objective of this study was to evaluate the program’s impact on retention, viral sup-
pression, and depression remission among patients with elevated depressive symptoms at anti-
retroviral therapy (ART) initiation after 6 months in care.
Study design
This study employed a staggered multiple baseline (pre-post) design to evaluate a pilot pro-
gram integrating depression screening and treatment into routine HIV primary care using
existing staff at two public health clinics in Lilongwe, Malawi [42]. Multiple baseline studies
use a time-series design that can be used for studies with multiple sites in which each site
intentionally receives the intervention at a different time point [42, 43]. This design can also
provide evidence of causal relationships where randomization is not possible and provides
stronger control for temporal trends [42, 43]. As such, the program rolled out in two phases, a
screening-only “control” phase and an active “intervention” phase. The screening control
phase launched at both clinics in April 2017. However, the launch of the intervention phase
was staggered, launching at Clinic A in November 2017 and at Clinic B in April 2018. (Fig 1)
Additional information on the study design is available in the published protocol paper [41].
Fig 1. Staggered multiple baseline study design.
https://doi.org/10.1371/journal.pone.0231872.g001
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Control phase:
During the control phase, providers screened patients for depression using the Patient
Health Questionnaire-9 (PHQ-9). The PHQ-9, a nine-item screening questionnaire that
assesses the presence and frequency of the nine Diagnostic and Statistical Manual of Mental
Disorders, Fourth Edition symptoms of major depression [44]. It has been widely used in the
region [2, 45, 46] and was recently validated in Malawi among patients with diabetes [47]. A
total score of 5–9 and�10 are considered indicative of mild depressive symptoms and moder-
ate to severe depressive symptoms, respectively[48]. Patients who endorsed the last question of
the PHQ-9, which asks about thoughts of being better off dead or hurting oneself, completed a
suicide risk assessment protocol (SRAP) with the providers. The SRAP guided providers’ eval-
uation of whether such thoughts were passive or active. During the control phase, ART provid-
ers were re-oriented to existing options for depression care within the Malawi primary care
system. This options theoretically include counseling and antidepressants, although in actual-
ity counseling consists of informal counseling by ART providers and antidepressants are rarely
prescribed. For patients with suicidality, providers were trained to respond based on the level
of severity, ranging from a brief safety assessment to immediate transport to the outpatient
psychiatric department at the district hospital.
During the intervention phase, ART providers (nurses or clinicians) used PHQ-9 scores at
ART initiation to triage patients by depressive severity. ART providers were trained to refer
participants with mild depressive symptoms (PHQ-9 score 5–9) to clinic-based lay health
workers or a project-employed counselor trained to provide an adapted problem-solving inter-
vention called Friendship Bench therapy [27, 29]. These counselors provided patient-centered
counseling that guided patients through recognizing problems, identifying their own solu-
tions, implementing those solutions, and assessing the outcome[29, 34]. Patients referred to
the Friendship Bench would ideally receive at least six counseling sessions. While these
patients were encouraged to return weekly for Friendship Bench therapy, patients set their
own appointments in line with the protocol’s patient-centered approach. For participants with
moderate to severe depressive symptoms (PHQ-9 score�10), ART providers were trained to
prescribe antidepressants (fluoxetine or amitriptyline) with appropriate dosing and dose
changes, using an algorithm-based care protocol. Under this protocol, providers used PHQ-9
scores and drug side effects to guide antidepressant prescription, titrating the antidepressant
dose by monitoring depressive symptoms and antidepressants side effects at each clinic visit
[31–33] (Table 1). Patients who started antidepressants were meant to be reevaluated monthly
at their ART visits when they would be re-prescribed antidepressants for at least three months.
Additional information on the combined medication and counseling depression treatment
program has previously been published [22].
Study population
From April 2017 through November 2018, all non-pregnant adults newly initiating ART at the
study sites were eligible to be included in the program evaluation. Pregnant women were
Table 1. Depression treatment overview, by phase.
Score Depressive
Severity
Screening “Control” Phase Active “Intervention”
Phase
0–4 No or minimal None None
5–9 Mild No formal depression treatment–could include informal clinician counseling or, rarely, antidepressant
prescription
Friendship Bench
10–
27
Moderate to severe Antidepressants
https://doi.org/10.1371/journal.pone.0231872.t001
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excluded as they typically test for HIV at a specific antenatal care clinic and continue to receive
ART as part of their antenatal care. This analysis is restricted to participants who completed
depression screening and had elevated depressive symptoms (PHQ-9 score� five) at ART ini-
tiation. Participants were placed in the “control” or “intervention” groups based on the phase
during which they initiated ART.
Control group: Includes participants with elevated depressive symptoms who initiated ART
at either clinic during the screening “control” phase (e.g. at Clinic A between April 2017 and
November 2017 and at Clinic B between April 2017 and April 2018).
Intervention group: Includes participants with elevated depressive symptoms who initiated
ART at either clinic after the launch of the treatment program during the active “intervention”
phase (e.g. at Clinic A after November 2017 and at Clinic B after April 2018).
Data collection
As an implementation science study, the primary objective was to assess the impact of an inter-
vention that could readily (and rapidly) be adopted and integrated into routine care in the
public sector setting [49, 50]. Just as the program made use of existing clinical staff and sys-
tems, the evaluation was intentionally designed to influence and disrupt the provision of care
as little as possible by collecting only data that was already routinely captured during clinical
care and using research staff only to consent patients and abstract data. Specifically, we did not
conduct baseline interviews or schedule six-month follow-up interviews, which would have
limited enrollment and potentially brought participants back into care, biasing our primary
outcome measure of HIV care engagement. Research assistants at the study sites approached
potential participants during ART initiation to invite them to allow their clinical data to be
used in the program evaluation. Research assistants abstracted routinely collected clinic data
on depression and HIV care from consenting participants’ clinical records over a 13-month
period, starting at ART initiation. Abstracted data included appointment dates, expected
return dates, ART pills dispensed, PHQ-9 scores, and depression treatment provided. At ART
initiation and each subsequent ART appointment, providers give patients a follow-up appoint-
ment date and a sufficient supply of ART. Generally, for the first six months of care, new ART
patients receive a 30-day supply of ART and a return appointment date in 30 days at each
appointment. Most often, patients need to attend monthly ART refill appointments for their
first six months of care in order to maintain their ART supply. Additionally, we obtained elec-
tronic medical record data from the clinical sites to ensure the quality and completeness of the
abstracted data.
Measures
Exposures. Adequate Friendship Bench therapy should consist of six sessions over the
first six months in care and a standard course of antidepressants should consist of at least three
consecutive months of antidepressant prescription with dosage adjustments as necessary. For
the analysis purposes, we have operationalized the intervention exposure as follows:
Intent-to-treat: Intervention group participants were considered “exposed” to the interven-
tion if they initiated ART during the intervention phase. Control group participants were con-
sidered “unexposed” to the intervention if they initiated ART during the control phase.
Treatment started: The intervention group included participants who either had: 1) mild
depressive symptoms at ART initiation who started Friendship Bench therapy at ART initia-
tion or 2) moderate to severe depressive symptoms who were prescribed antidepressants at
ART initiation. The control group participants did not start Friendship Bench therapy or anti-
depressants at ART initiation.
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As treated: The intervention group included participants who attended at least their first
follow-up appointment and either had: 1) mild depressive symptoms at ART initiation and at
least two Friendship Bench therapy sessions over their first six months in care or 2) moderate
to severe depressive symptoms at ART initiation and were prescribed at least two months of
antidepressants over their first six months in care. The control group included participants
who attended at least their first follow-up appointment, but did not have at least two friendship
bench sessions or two months of antidepressant prescription over their first six months in
care. Those participants who did not attend at least their first follow-up visit were excluded.
While this definition was less stringent than the ideal course of treatment, this definition
allowed for a more refined comparison of those who received early and consistent depression
treatment compared to those who had not.
Outcomes. Retention was defined as never being more that 14 days late to an appoint-
ment through 6 months in care. Maintaining a consistent ART supply was defined as never
more than 5 days without ART in the first 6 months, calculated from the cumulative days’ sup-
ply of ART dispensed at each appointment in the first 6 months and the time between appoint-
ments. In alignment with the PEPFAR definition of “currently on treatment” [51], participants
were currently on ART 6 months after ART initiation if they attended an appointment and
received a supply of ART that would last through the 6 month mark. Viral suppression was
defined as a viral load of less than 1,000 copies/mL drawn after at least five and a half months
(166 days) in care. Depression remission was defined as a PHQ-9 score of less than five taken
after at least five and a half months (166 days) in care, to allow for completion of the acute
phase of treatment and maintenance of that response [52]. Additionally, we examined the pro-
portion of scheduled HIV appointments attended within one week during the first 6 months
of care and the ART pill possession ratio, the proportion of the first 6 months (183 days) since
ART initiation with ART in hand, calculated from cumulative pills dispensed at each ART
appointment through 6 months.
Covariates. Due to the implementation science nature of this study, we only abstracted
routinely collected clinical data. Measured covariates included the healthcare facility where
patients received ART (Clinic A or B), months since program launch at ART initiation, gen-
der, age, baseline depressive severity at ART initiation (mild or moderate to severe), and base-
line presence of suicidal thoughts at ART initiation. Presence of suicidal thoughts was defined
as any endorsement of the ninth question of the PHQ-9, “During the past two weeks, how
many days have you been bothered by thoughts that you would be better off dead or of hurting
yourself in some way?”
Data analysis
The main analysis followed an “intent-to-treat” approach, classifying participants according to
screening “control” vs. active “intervention” phase (unexposed vs. exposed to the program)
without regard to actual treatment received. Although patients identified with elevated depres-
sive symptoms late in the control phase could theoretically have received depression care from
providers during the intervention phase during their first six months of care, in practical
terms, depression treatment was only provided to patients newly entering care. Furthermore,
we monitored crossover between groups. We first completed unadjusted, tabular comparisons
of HIV care and depression outcomes in the intervention group relative to the control group.
We then used log-binomial models to estimate adjusted risk ratios comparing the probability
of the primary outcome, retention with viral suppression, as well as the probability of other
secondary HIV care outcomes in the intervention group compared to the control group. Since
the evaluation employed a staggered multiple baseline design, with the intervention launching
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at different dates at the two clinics, all models were adjusted for clinic and months since pro-
gram launch to allow for the assessment of and potential correction for any secular trend in
outcomes (“confounding by history”). While the study design should have produced compara-
ble control and intervention groups, we did additionally consider controlling for measured
covariates. To separately evaluate the impact of the Friendship Bench and the antidepressant
treatment, we then stratified the primary analysis by depressive severity at baseline (mild or
moderate to severe depressive symptoms). Other secondary analyses used a “treatment started”
approach, comparing those who actually started Friendship Bench therapy or antidepressants
to those that did not in both phases and then an “as treated” approach, comparing those who
received at least two Friendship Bench therapy sessions or two months of antidepressants to
patients who did not in both phases, restricted to only those who attended at least their first
follow-up visit.
Outcome data for those who transferred or died in the first 6-months of care were treated
as missing. To address missing outcome data, we used multiple imputation by chained equa-
tions (MICE) to fill missing values using logistic regression imputation methods [53]. We
imputed values based on phase, healthcare facility, months since program launch at ART initi-
ation, age, sex, baseline depressive severity at ART initiation and baseline presence of suicidal-
ity at ART initiation. We generated 18 imputed datasets to ensure the number of imputed
datasets was at least as large as the percentage of incomplete information for the main out-
come, “retention with viral suppression” [54]. To verify that this was sufficient, we confirmed
that the number of imputed datasets was also larger than the parameter-specific fraction of
missing information for all parameters included in the final model [55].
All analyses were performed using STATA IC 14.
Ethical review
The National Health Sciences Research Committee of Malawi (NHSRC) and the Biomedical
Institutional Review Board (IRB) of the University of North Carolina at Chapel Hill approved
the study protocol. All participants gave written informed consent to allow the abstraction of
their clinical data. The evaluation only used de-identified clinic data to ensure the protection
of participants’ identities and confidentiality. Patients with depression received depression
care regardless of whether or not they provided consent for their data to be abstracted.
Results
Depression screening
Over the course of the program, 2414 patients newly initiated ART (Fig 2). Of these new initia-
tors, 2067 (86%) consented to allow their data to be abstracted to evaluate the program. Nearly
all of those who consented (96%) were screened with the PHQ-9 appropriately. Among those
who completed the PHQ-9 screening, the prevalence of mild depressive symptoms (PHQ-9
score 5–9) was 19% and the prevalence of moderate to severe depressive symptoms (PHQ-9
score� 10) was 6%. Only those participants with elevated depressive symptoms (PHQ-9
score� 5) are included in this analysis (N = 501).
Participant characteristics
Of the 501 consenting participants with elevated depressive symptoms, the control group con-
sisted of the 290 who initiated ART during the control phase and the intervention group con-
sisted of the 211 who initiated during the intervention phase (Table 2). As the program
launched later at Clinic B, a larger proportion (75%) of the intervention group were from
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Clinic A. Otherwise, the two groups appear very similar. About 43% of participants were male.
The average age of participants was 33.8 years. Nearly all participants were classified as asymp-
tomatic (Stage I) for HIV at ART initiation, according to the World Health Organization’s
(WHO) HIV clinical stages for HIV surveillance [56]. At ART initiation, 74% of participants
had mild depressive symptoms, only around 1% of participants had severe depressive symp-
toms and 21% of participants reported suicidality.
Depression treatment exposure
Initiating depression treatment. Among the control group, 89% of participants with
mild depressive symptoms and 80% participants with moderate to severe depressive symptoms
received some additional counseling by ART clinicians (“standard depression care” during the
Fig 2. Evaluation enrollment.
https://doi.org/10.1371/journal.pone.0231872.g002
Table 2. Participant characteristics (N = 501).
n(%) or mean (sd) Overall Control Group Intervention Group
Overall 501 290 211
Clinic
Clinic A 276 (55%) 116 (40%) 160 (76%)
Clinic B 225 (45%) 174 (60%) 51 (24%)
Sex
Male 214 (43%) 125 (43%) 89 (42%)
Female 287 (57%) 165 (57%) 122 (58%)
Age 33.8 (9.5) 33.6 (10.0) 34.0 (8.7)
WHO Disease Stage
I 498 (99%) 288 (99%) 210 (>99%)
II-IV 3 (1%) 2 (1%) 1 (<1%)
Baseline Depression Severity
Mild (PHQ-9: 5–9) 370 (74%) 214 (74%) 156 (74%)
Moderate (PHQ-9: 10–19) 126 (25%) 71 (24%) 55 (26%)
Severe (PHQ-9: 20–27) 5 (1%) 5 (2%) 0 (0%)
Baseline Suicidality
No thoughts 397 (79%) 228 (79%) 169 (80%)
Passive thoughts 53 (11%) 33 (11%) 20 (9%)
Active thoughts 46 (9%) 27 (9%) 19 (9%)
Not assessed with SRAP 5 (1%) 2 (1%) 3 (1%)
SRAP = Suicide Risk Assessment Protocol
https://doi.org/10.1371/journal.pone.0231872.t002
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control phase) (Table 3). During this phase, only 18% (n = 14) of those with moderate to severe
depressive symptoms started amitriptyline during the control phase and most (n = 11) started
at a subtherapeutic dose of 25 mg.
Most of the intervention group started the appropriate treatment as defined by the inter-
vention protocol during the intervention phase. During this phase, 86% of participants with
mild depressive symptoms started Friendship Bench therapy and nearly all (96%) participants
with moderate to severe depressive symptoms started antidepressants. All of the participants
with moderate to severe depressive symptoms who started antidepressants at ART initiation
started at a minimal effective dose (operationally defined as a daily oral dose of either 20 mg of
fluoxetine or 50 mg of amitriptyline).
Provision of ongoing depression treatment. Few patients in the intervention group con-
tinued to receive ongoing depression treatment during the intervention phase after ART initia-
tion. Only 42% of participants referred to the Friendship Bench attended three or more
therapy sessions (Table 4). Of those who were prescribed antidepressants, less than a third of
Table 3. Depression treatment initiation.
N (%) Control Group Intervention Group
Mild depressive symptoms (PHQ-9: 5–9) 214 (100%) 156 (100%)
Counseling by clinician 191 (89%) 15 (10%)
Friendship Bench therapy - 134 (86%)
Antidepressant� 2 (1%) 2 (1%)
None�� 21 (10%) 5 (3%)
Moderate to severe depressive symptoms (PHQ-9:�10) 76 (100%) 55 (100%)
Counseling by clinician 60 (79%) 2 (4%)
Friendship Bench therapy - 0 (0%)
Antidepressant��� 14 (18%) 53 (96%)
None 2 (3%) 0 (0%)
�Includes those who received both antidepressants and the Friendship Bench (n = 2).
��Those with missing baseline treatment plan (n = 4) treated as none.
���Includes those who received both antidepressants and counseling by clinician (n = 8) or both antidepressants and the Friendship Bench (n = 4).
https://doi.org/10.1371/journal.pone.0231872.t003
Table 4. Depression treatment over time.
Control Group Intervention Group
Of those directed to Friendship Bench:� - 140 (100%)
Number of sessions attended
1 - 60 (43%)
2 - 21 (15%)
�3 - 59 (42%)
Of those prescribed antidepressants:�� 16 (100%) 55 (100%)
Number of months antidepressants provided
1 13 (81%) 23 (42%)
2 2 (13%) 15 (27%)
�3 1 (6%) 17 (31%)
�Includes those who were referred to the Friendship Bench and those who were both prescribed antidepressants and
referred to the Friendship Bench.
��Includes those who were prescribed antidepressants and those who were both prescribed antidepressants and were
referred to the Friendship Bench.
https://doi.org/10.1371/journal.pone.0231872.t004
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participants (n = 17) received three or more months of antidepressant prescription. Only six of
those participants received at least three consecutive months of the same antidepressant. Inad-
equate sustained treatment was in part due to poor appointment attendance, medication
stock-outs, and clinicians’ failure to identify patients with elevated depressive symptoms at fol-
low-up ART appointments. However, it did not appear that there was much crossover between
groups. None of the control participants ever started Friendship Bench therapy and very few
started antidepressants at ART initiation (n = 16) or at a follow-up visit (n = 6).
Program impact
Most HIV and mental health outcomes did not appear to differ between groups. (Table 5).
Retention in both arms was poor; approximately a third of participants in both groups
remained in care through 6 months. Just over half of the control group and just under half of
the intervention group were currently on ART at six months. Close to 40% of participants in
both the control and intervention phases maintained a consistent ART supply (never more
than 5 days without ART) through six months. Many participants had missing data for viral
suppression and depression remission after 5.5 months; only 36% (n = 181) of participants had
viral load draw after 5.5 months and 26% of participants (n = 132) had a measured PHQ-9
score. Among those with a measured viral load or PHQ-9 score after 5.5 months, respectively,
viral suppression and depression remission were high (>91%) in both groups. Findings were
similar when stratified by baseline depressive severity (mild or moderate to severe) and when
using a “treatment started” and an “as treated” approach. S1 Table–S4 Table.
To assess potential bias due to missing data from transferring or attending care without get-
ting a 6-month viral load or PHQ-9 assessment, we compared baseline information between
those with and without missing data. While a larger proportion of transfers were from Clinic
A, missing data did not appear to be associated with any other measured baseline characteris-
tics. S5 Table–S7 Table.
The final adjusted model controlled for clinic, months since program launch at ART initia-
tion, sex and baseline depressive severity. Both age and baseline presence of suicidality intro-
duced model instability. As age did not appear to be associated with any of the outcomes or
Table 5. Program impact on HIV and depression outcomes.
n(%) or mean (sd) Control Intervention
Retention: never >14 days through 6 months 91/266
(34%)
66/186
(35%)
HIV appointment attendance: average proportion of scheduled appointments
attended through 6 months (Range: 0–1)
0.57 (0.39) 0.59 (0.38)
Currently on ART: attended appointment prior to 6 months with next scheduled
appointment after 6 months
138/266
(52%)
87/186
(47%)
Consistent ART: never >5 days without ART through 6 months 112/266
(42%)
73/186
(39%)
ART pill possession: average proportion of days with ART through 6 months (Range:
0.16–1)
0.69 (0.35) 0.67 (0.37)
Viral suppression: VL < 1,000 copies/mL after 5.5 months, among those with a viral
load
108/115
(94%)
60/66 (91%)
Depression remission: PHQ-9 score < 5 after 5.5 months, among those with a PHQ-9
score
87/93 (94%) 37/38 (97%)
Transferred within the first 6 months of care: Control Phase n = 24; Intervention Phase n = 25; Denominators vary
due to viral loads not being drawn, the PHQ-9 not being administered, not having or attending a scheduled
appointment around 6 months.
https://doi.org/10.1371/journal.pone.0231872.t005
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program exposure, we ultimately removed it from the model. We only retained baseline
depressive severity in the final adjustment set as baseline presence of suicidality was highly cor-
related with baseline depressive severity.
In the adjusted “intent-to-treat” analysis, program exposure did not demonstrably affect
the primary outcome, retention with viral suppression at 6 months (Table 6). While no differ-
ence was evident for most of the secondary outcomes, the probability of currently being on
ART at 6 months and the ART pill possession ratio was significantly lower among the inter-
vention group than among the control group [RR 0.6(95%CI: 0.4–0.9) and Mean Difference
-0.1(95%CI: -0.3–0), respectively]. Correction for missing data with multiple imputation did
not have a significant impact on any of the outcomes. When stratified by baseline severity,
only the probability of being on ART at 6 months was significantly lower during the interven-
tion phase than during the control phase [RR 0.33(95%CI: 0.13–0.83)] among those with mod-
erate to severe depressive symptoms at baseline. S8 Table. The “treatment started” and “as
treated” approaches generally showed similar results. S9 Table and S10 Table.
Discussion
We investigated the impact of a program integrating depression management into HIV care
initiation on 6-month HIV care and depression outcomes. Clinic staff screened nearly all
patients for depression, documenting the prevalence of mild and moderate to severe depres-
sive symptoms among people newly initiating ART. During the intervention phase of the pro-
gram, they successfully started the majority of the intervention group on the appropriate
depression treatment. However, providing ongoing treatment proved more challenging, and
few patients received a standard course of antidepressants or attended a sufficient number of
Friendship Bench therapy sessions. Retention was very low in both the intervention and con-
trol groups. Nearly all participants who did remain in care and had a 6-month viral load
drawn and PHQ-9 assessment achieved viral suppression and depression remission. However,
the evaluation did not yield evidence that the integrated depression treatment program
improved 6-month HIV care or depression outcomes among the intervention group com-
pared to the control group.
The successful integration of depression screening allowed this evaluation to document the
prevalence of depression among people newly initiating ART. A growing body of research is
beginning to establish the magnitude of mental health disorders in Malawi. In Malawian pri-
mary care settings, a third of all patients have a common mental disorder, most commonly
Table 6. Effect of intervention on HIV care and depression outcomes.
Outcome Adjusted� Imputation��
RR or Mean Difference (95%
CI)
Retention: never >14 days through 6 months 1.1 (0.6–1.9) 1.1 (0.6–1.9)
HIV appointment attendance: average proportion of scheduled appointments
attended through 6 months
0.0 (-0.1–0.2) 0.0 (-0.1–0.1)
Currently on ART: attended appointment prior to 6 months with next scheduled
appointment after 6 months
0.6 (0.4–0.9) 0.6 (0.4–0.9)
Consistent ART: never >5 days without ART through 6 months 0.8 (0.5–1.2) 0.8 (0.5–1.3)
ART pill possession: average proportion of days with ART through 6 months
(Range: 0.16–1)
-0.1 (-0.3–
0.0)
-0.1 (-0.4–
0.1)
�Adjusted for clinic, months since program launch (quadratic term), sex, and baseline depressive severity
��Further corrected for missing data via multiple imputation.
https://doi.org/10.1371/journal.pone.0231872.t006
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depression [57]. However, few studies have estimated the prevalence of depression among the
general adult population of people living with HIV. We found that around a quarter of people
newly initiating ART at the study sites had mild to severe depressive symptoms. This finding is
only slightly higher than estimates from various subpopulations (adolescents, pregnant
women, adults receiving HIV care) of people living with HIV in Malawi [1–3] and supports
other sub-Saharan regional estimates of depression prevalence [5]. Such evidence indicates a
clear need for depression treatment among people living with HIV.
The integration of depression screening and treatment initiation at the time of ART initia-
tion appeared feasible. During ART initiation, nearly all of the 2067 participants who consented
to participate in the study were successfully screened for depression. Further, nearly all inter-
vention participants started the treatment appropriate for their depressive severity at ART initi-
ation. Factors that may have contributed to this success include the effective utilization of
existing ART initiation processes and the creation of a collaborative training environment [22].
For example, after careful study of patient flow, we designed the initial PHQ-9 screening to be
shared by the HTC counselors and the ART providers, distributing the additional work and
time burden. We also ensured that every HIV provider received training in how to administer
and interpret the PHQ-9, provide depression treatment, and manage depression symptoms
over time–creating opportunities for iterative learning and ongoing support [22]. Another task-
sharing study in Uganda found that both depression screening by lay workers and antidepres-
sant treatment initiation by ART provider were feasible, a success the researchers attributed to
ongoing training and appropriate mentorship [33]. As such, using non-psychiatric specialists to
screen and triage cases of depressions appears possible in this sub-Saharan setting.
While effective integration into existing processes was key to the success of depression
screening and treatment initiation, the aspects of existing infrastructure and supply manage-
ment that the program was unable to effectively utilize hampered the provision of sustained
depression treatment. Providers at the study sites typically rely on an electronic medical rec-
ords (EMR) system to provide ART, which did not incorporate PHQ-9 screening or depres-
sion treatment and thus did not alert providers to re-assess depressed patients returning for
care. Despite developing a system of marking patients’ health passports so that those needing
depression treatment re-evaluation could be identified, providers struggled to re-identify
depressed patients returning for ART care[22]. Very few studies on task-shifting models of
care in the region have relied on existing staff (as opposed to study employed staff) or assessed
the provision of depression treatment over time. For example, the study evaluating different
task-sharing strategies for depression treatment in Uganda only reported on depression treat-
ment initiation [33], making comparisons challenging. Other implementation science studies
will need to track and assess the provision of treatment over time.
Antidepressant stock-outs were also common and problematic. While the Malawi Ministry
of Health has committed to making antidepressants freely available at health center pharmacies
[40], ensuring their availability was complicated and required substantial coordination, often
beyond the scope of work of the health center pharmacist. Other countries such as Mozambique
with similar policies on the provision of antidepressants have also experienced challenges stock-
ing these medications at the district or clinic level [58]. Another task-shifting depression pro-
gram in Tanzania also experienced anti-depressant stock-outs [31]. Greater engagement and
investment of health sector stakeholders involved in the procurement, supply and distribution
of drugs such as Malawi’s Central Medical Stores is required to ensure antidepressant stocks are
maintained to ensure the success and safety of depression treatment programs.
The clinics also found it challenging to provide proper Friendship Bench therapy, in part
due to community health care workers’ availability and in part due to patients’ ability to return
to the clinic for therapy sessions, in light of financial, time, and transport barriers[59]. As the
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community health workers already had a very high workload and often traveled off-site to run
various Ministry of Health initiatives, the one program-employed counselor at each site ulti-
mately provided the majority of the therapy sessions. Community health workers are often
already overloaded with work and are at risk of becoming additionally overburdened when
drawn into task-sharing models of care [60, 61], as was potentially the case at the study sites.
Furthermore, while the original Friendship Bench protocol called for 6 weeks of weekly ther-
apy sessions [29], patients were reluctant to make additional trips to the clinic primarily due to
time and transportation barriers. This resulted in scheduling Friendship Bench sessions to
coincide with the patients’ monthly ART refill appointments. While attending weekly sessions
appeared acceptable in the original Friendship Bench program [29], it is difficult to tell from
other adaptations as they may have incentivized attending sessions with reimbursement [62].
These findings highlight the importance of implementation science research to establish the
real-world feasibility of task-shifting depression care for people living with HIV.
As implemented, the program did not appear to improve HIV care or depression outcomes,
as few patients received depression treatment as intended. Studies in the region have found
that similar programs, albeit with higher fidelity to their treatment protocols, have been effec-
tive at treating depression [35, 36]. In our study, nearly all participants achieved depression
remission, regardless of depression treatment. As many of these other evaluations of depres-
sion treatment programs were quite small or did not include control arms [35, 36], it is possi-
ble that depressive symptoms could have improved in the absence of depression treatment.
However, it should be noted that we could have overestimated six-month depression remis-
sion if patients who did not remain in care were more likely to have persistent depressive
symptoms. In regards to the program’s impact on HIV outcomes, the literature on linking
depression treatment to improvements across the HIV care cascade is mixed [13–16, 62–69].
A recent meta-analysis of depression treatment interventions for people living with HIV in
sub-Saharan Africa also did not find that interventions improve viral suppression, though they
did conclude that the programs with an ART adherence component had the greatest impact
on HIV outcomes [36]. As it was impossible for the program to have a pure control group in
which patients were denied depression treatment, it is possible that providers discussed the
depression screening results with participants or provided brief additional ART adherence
counseling. While even unstructured additional patient attention has the potential to impact
engagement in care, it is no substitute for evidence-based depression treatment and adherence
counseling interventions. Further research is needed to understand the factors that influenced
adherence to the program protocol and to identify the more effective ways to implement
depression treatment programs that will improve depression and HIV care outcomes.
Retention in care was remarkably low in both of the study phases; only a quarter of patients
achieved retention and viral suppression at 6 months. Aligned with PEPFAR’s less stringent
definition of being in care at 6 months (our “currently on ART” measure) [51], only half of
patients were retained at six months. These estimates are much lower than national 12-month
estimates from 2018, which found that 65% of adults who initiated ART were still in care at 12
months[70]. However, as our entire study population had elevated depressive symptoms, it
possible that depression is responsible for this difference in retention. The program did not
appear to improve HIV care engagement, even when using the “treatment started” or “as
treated” approach, and in the main analysis the intervention group was significantly less likely
to currently be on ART at 6-months than the control group. It is possible that this population
faced other barriers to care that were more relevant and difficult to overcome, such as human
resource and institutional challenges, distance to the clinic, lack of support, stigma and fear of
HIV status disclosure [71–74]. Nonetheless, there is a distinct need for urgent action to
improve early retention in care for people living with HIV and depression.
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Limitations
The results should be considered in light of several limitations. Although the study’s design
was not guided by a formal implementation science framework, the study was designed in con-
gruence with the key principles of implementation science, using methods that would promote
the systematic uptake of evidence-based practices (e.g. the Friendship Bench and algorithm-
based care) into routine care [75, 76]. In line with the implementation science-inspired design
of the study and our efforts not to unduly influence the provision of or engagement in care, all
of the measures were drawn from routinely collected medical chart data. As we did not con-
duct baseline interviews or schedule six-month follow-up interviews, we captured limited
information on potential confounders. A large proportion of patients did not have six-month
viral loads or PHQ-9 scores due to either dropout or provider failure to refer patients for viral
load testing or screen patients appropriately. Still, the multiple baseline design should have
protected against confounding from unmeasured confounders by producing balanced charac-
teristics across phases, as evident from similar characteristics of intervention and control
groups seen in Table 2. Additionally, the program struggled to establish a sense of ownership
among providers, develop capacity to manage depression treatment over time, and ensure the
availability of antidepressants, which may have impacted providers’ adherence to the depres-
sion treatment protocol [22]. As an extension of this challenge, ART providers administered
the six-month PHQ-9, so part of the observed reduction in PHQ-9 scores could be due to less
careful administration.
All of the HIV engagement measures may have been influenced by participants who sought
care at another facility without formally transferring their records. These “silent transfers”
would have been misclassified as being out of care. However, as the rate of silent transfers
should not have varied between groups, this potential measurement error should not have
introduced bias into the analyses.
Conclusion
This experience demonstrated that while it is feasible to integrate depression screening and
treatment initiation into ART initiation, providing ongoing depression treatment over time is
challenging; very few patients received ongoing depression treatment for many of the reasons
discussed above. In this setting, it is clear that in order for such a program to be successful
additional resources are needed to support ongoing capacity building, ensure the availability
of Friendship Bench counselors and antidepressants, encourage patient engagement in the
full-course of treatment, and further integrate into the electronic medical records system.
Additionally, further research is needed to explore the other factors that potentially govern
both the implementation of and engagement with such a program. While the evaluation did
not yield evidence that the program improved HIV care or depression outcomes in a real
world clinic setting, depression treatment in sub-Saharan Africa is efficacious for improving
mental health and engagement in HIV care in more controlled research environments [35].
Further, this program targeted patients newly initiating ART, often at the highest risk for loss
to care. Further research could explore whether other patient populations may benefit from
depression treatment, such as those returning for care with elevated depressive symptoms or
whether depression treatment for people living with HIV may be more effective if it includes a
specific component supporting ART adherence or HIV care engagement. Moving the field of
mental health care in LMICs forward, similar implementation science studies will be increas-
ingly important as we strive to understand and test the best ways to implement evidence-based
depression treatment protocols for this vulnerable population.
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